EGFR and non-small cell lung carcinoma: Current practice recommendations by the International Association for the Study of Lung Cancer (IASL) and the European Society for Medical Oncology (ESMO), among others, are molecular diagnostic testing to identify patients diagnosed with advanced NSCLC eligible for first- or second-line EGFR TKI targeted therapy [15,16].